Skip to main content
Top
Published in: Rheumatology International 2/2017

01-02-2017 | Observational Research

The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study

Authors: Yan Liang, Rui-Xue Leng, Hai-Feng Pan, Dong-Qing Ye

Published in: Rheumatology International | Issue 2/2017

Login to get access

Abstract

This study aims to estimate the prevalence of serositis and identify risk factors for serositis in a large cohort of systemic lupus erythematosus (SLE) patients. A cross-sectional study was conducted based on the medical records of patients hospitalized with SLE at the First Affiliated Hospital of Anhui Medical University and Anhui Provincial Hospital. Patients were diagnosed with serositis when they presented with symptoms and signs of pleuritis or/and pericarditis. We explored factors associated with the generation and quantity of serositis by using binary and ordinal logistic regression analysis. Among the 1668 lupus patients, 298 have serositis. Active lupus disease, fever (≥38 °C) and high D-dimer were all significantly associated with the generation and quantity of serositis. Male gender was independent significant risk factor for pleuritis but not for pericarditis, while low complement C4 and high erythrocyte sedimentation rate (ESR) were risk factors for pericarditis rather than for pleuritis. The possible prevalence of serositis in patients with SLE was 17.9%. The significant associations of active lupus disease, fever (≥38 °C) and high D-dimer with serositis suggest that higher disease activity and hypercoagulability may both contribute to the generation and development of serositis in SLE. The risk factors for pleuritis and pericarditis in SLE are similar but not identical.
Literature
1.
go back to reference Liang Y, Xu WD, Peng H, Pan HF, Ye DQ (2014) SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol 44:1265–1275CrossRefPubMed Liang Y, Xu WD, Peng H, Pan HF, Ye DQ (2014) SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol 44:1265–1275CrossRefPubMed
2.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed
3.
go back to reference Crozier IG, Li E, Milne MJ, Nicholls MG (1990) Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 65:1145–1148CrossRefPubMed Crozier IG, Li E, Milne MJ, Nicholls MG (1990) Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 65:1145–1148CrossRefPubMed
4.
go back to reference Zhao J, Bai W, Zhu P et al (2016) Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus. Lupus 25:652–657CrossRefPubMed Zhao J, Bai W, Zhu P et al (2016) Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus. Lupus 25:652–657CrossRefPubMed
5.
6.
go back to reference Weich HS, Burgess LJ, Reuter H, Brice EA, Doubell AF (2005) Large pericardial effusions due to systemic lupus erythematosus: a report of eight cases. Lupus 14:450–457CrossRefPubMed Weich HS, Burgess LJ, Reuter H, Brice EA, Doubell AF (2005) Large pericardial effusions due to systemic lupus erythematosus: a report of eight cases. Lupus 14:450–457CrossRefPubMed
7.
go back to reference Clarke A (2004) Proposed modifications to 1982 ACR classification criteria for systemic lupus erythematosus: serositis criterion. Lupus 13:855–856CrossRefPubMed Clarke A (2004) Proposed modifications to 1982 ACR classification criteria for systemic lupus erythematosus: serositis criterion. Lupus 13:855–856CrossRefPubMed
8.
go back to reference Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
9.
go back to reference Man BL, Mok CC (2005) Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 14:822–826CrossRefPubMed Man BL, Mok CC (2005) Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 14:822–826CrossRefPubMed
10.
go back to reference Ngandeu MS, Ndobo P, Gabay C (2009) Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaoundé-Cameroon. Clin Rheumatol 28:465–468CrossRefPubMed Ngandeu MS, Ndobo P, Gabay C (2009) Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaoundé-Cameroon. Clin Rheumatol 28:465–468CrossRefPubMed
11.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640CrossRefPubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640CrossRefPubMed
12.
go back to reference Li LH, Pan HF, Li WX, Li XP, Xu JH, Ye DQ (2009) Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population. Clin Rheumatol 28:1301–1307CrossRefPubMed Li LH, Pan HF, Li WX, Li XP, Xu JH, Ye DQ (2009) Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population. Clin Rheumatol 28:1301–1307CrossRefPubMed
13.
go back to reference Glauser FL, Otis PT, Levine RI, Smith WR (1976) Coagulation factors and fibrinogen in pleural effusions. Respiration 33:396–402CrossRefPubMed Glauser FL, Otis PT, Levine RI, Smith WR (1976) Coagulation factors and fibrinogen in pleural effusions. Respiration 33:396–402CrossRefPubMed
14.
go back to reference Strange C, Baumann MH, Sahn S, Idell S (1995) Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease. Am J Crit Care Med 151:508–515CrossRef Strange C, Baumann MH, Sahn S, Idell S (1995) Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease. Am J Crit Care Med 151:508–515CrossRef
15.
go back to reference Idell S, Girard W, Koenig K, McLarty J, Fair DS (1991) Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 144:187–194CrossRefPubMed Idell S, Girard W, Koenig K, McLarty J, Fair DS (1991) Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 144:187–194CrossRefPubMed
16.
go back to reference Tillet WS, Sherry S, Read CT (1951) Use of streptokinase-streptodornase in treatment of postpneumonic empyema. J Thorac Surg 21:275–297 Tillet WS, Sherry S, Read CT (1951) Use of streptokinase-streptodornase in treatment of postpneumonic empyema. J Thorac Surg 21:275–297
17.
go back to reference Petelin A, Johnson DH, Cunha BA (2013) Fever of unknown origin (FUO) due to systemic lupus erythematosus (SLE) presenting as pericarditis. Heart Lung 42:152–153CrossRefPubMed Petelin A, Johnson DH, Cunha BA (2013) Fever of unknown origin (FUO) due to systemic lupus erythematosus (SLE) presenting as pericarditis. Heart Lung 42:152–153CrossRefPubMed
Metadata
Title
The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study
Authors
Yan Liang
Rui-Xue Leng
Hai-Feng Pan
Dong-Qing Ye
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3630-0

Other articles of this Issue 2/2017

Rheumatology International 2/2017 Go to the issue